

5 August 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management

Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents July 2011

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests							
	95-08	2009	2010	2011	Total		
Submitted	69	11	21	16	117		
Advice given	65	8	18	13	104		

Initial evaluation								
	95-08	2009	2010	2011	Total			
Full	110	14	16	3	143			
(Submitted)								
Abridged/	10	1	2	1	14			
generics								
(Submitted)								
Withdrawals	12	0	1	0	13			
Positive	91	13	14	14	132			
opinions								
Negative	1	0	0	0	1			
opinions								

Marketing authorisations							
	95-08	2009	2010	2011	Total		
Granted	88	12	9	14	123		
Withdrawals	2	0	4	0	6		
Not renewed	2	0	0	0	2		

Extensions								
	95-08	2009	2010	2011	Total			
Submitted	60	12	3	3	77			
Withdrawals	2	1	1	0	4			
Positive	40	7	8	3	58			
opinions								
Negative	0	0	0	0	0			
opinions								

An agency of the European Union

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom **Telephone** +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8447 **E-mail** info@ema.europa.eu **Website** www.ema.europa.eu



© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.

Variations – applications submitted							
	95-08	2009	2010	2011	Total		
Туре ІА	339	32	76	71	670		
Туре ІВ	557	41	63	48	070		
Туре II	210	40	26	13	289		
Transfers	11	3	8	3	25		

Renewals								
	95-08	2009	2010	2011	Total			
Submitted	50	18	7	10	85			
Positive opinions	48	17	8	7	80			
Negative opinions	0	0	0	0	0			

Arbitrations and Community referrals							
	95-08	2009	2010	2011	Total		
Referrals submitted	38	9	12	9	68		
Opinions reached ¹	20	15 (5)	11 (1)	8	54 (6)		

¹ Re-examination of opinions in brackets

Substances considered as not falling within the scope of Regulation (EC) No 470/2009					
	2011	Total			
Submitted	4	4			
Agreed	7	7			
Scientific advice recommended 0 0					

MUMS/ Limited market classification						
	2011	Total				
Positive with financial incentives	6	6				
Positive without financial	9	9				
incentives						
Negative	1	1				

Establishment of MRLs for new substances									
	95-08 2009 2010 2011 Total								
Submitted	66	4	3	1	74				
Withdrawals	5	0	0	0	5				
Positive	54	2	2	3	61				
opinions ²									
Negative	7	0	0	0	7				
opinions ³									

Extensions / modifications/extrapolations of MRLs								
	95-08	2009	2010	2011	Total			
Submitted	98	2	10	4	114			
Withdrawals	4	0	0	0	4			
Positive	113	3	3	5	124			
opinions ²								
Negative	6	0	0	0	6			
opinions								
Extrapolations	50	0	0	0	50			

provisional maximum residue limits previously established

 ² Including opinions recommending the extension of the expiry date for provisional MRLS or definitive MRLs for substances with previously provisional maximum residue limits
 ³ Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits provisional

CVMP opinions in 2011 on medicinal products for veterinary use

Positive opinions

Pro	oduct	•	Marketing	The	erapeutic area	EV/	IA/CVMP	Eu	ropean Commission
FIC	duct	•	authorisation	•	Target species				•
•	Invented name INN		holder	•	Summary of	•	Validation Opinion	•	Opinion received Date of decision
					indication	•	Active time	•	Notification
						٠	Clock stop	٠	Official Journal
•	CaniLeish	٠	Virbac S.A.	•	Dogs	٠	17/03/2010	٠	13/01/2011
				•	Vaccine against	•	12/01/2011	•	14/03/2011
					Leishmania infection	٠	210	٠	17/03/2011
						•	91	•	OJ C 184/15
•	ZULVAC 1 + 8	٠	Pfizer Limited	•	Sheep	٠	18/03/2010	٠	13/01/2011
	Ovis			•	Vaccine for prevention	٠	12/01/2011	٠	14/03/2011
					of viraemia caused by	٠	180	•	17/03/2011
					Bluetongue Virus	٠	119	٠	OJ C 184/15
					serotypes 1 and 8				
•	BLUEVAC BTV8	•	CZ	•	Cattle, sheep	•	17/01/2009	•	10/02/2011
			Veterinaria	•	Vaccine for active	•	09/02/2011	•	14/04/2011
			S.A		immunisation against	٠	210	•	18/04/2011
					bluetongue disease	•	543	•	OJ C 184/15
•	Procox	٠	Bayer Animal	•	Dogs	٠	16/02/2010	•	11/02/2011
•	Emodepside		Health GmbH	•	Treatment of dogs	٠	09/02/2011	•	20/04/2011
	and toltrazuril				when mixed parasitic	•	210	•	28/04/2011
					infections, caused by	٠	148	٠	OJ C 184/15
					certain specific				
					roundworms and				
					coccidia are suspected				
					or demonstrated				
•	Veraflox	٠	Bayer Animal	•	Dogs, cats	٠	19/05/2009	•	11/02/2011
•	Pradofloxacin		Health GmbH	•	Treatment for dogs	٠	14/07/2010	٠	12/04/2011
					and cats with	•	205	•	14/04/2011
					particular infections	•	217	•	OJ C 184/15
					caused by certain	•	09/02/2011		
					specific and	(re			
					susceptible pathogens		nsideration)		
•	Zuprevo	•	Intervet	•	Pigs, cattle	•	16/02/2010	•	10/03/2011
•	Tildipirosin		International	•	Treatment of bacterial	•	08/03/2011	•	06/05/2011
			BV		infections in the	•	210		
					respiratory tract in	•	177		
					pigs and cattle				
•	CERTIFECT	•	MERIAL SAS	•	Dogs	•	16/03/2010	•	10/03/2011
•	Fipronil, (S)-			•	Treatment and	•	09/03/2011	•	06/05/2011
	methoprene,				prevention of	•	210		
	amitraz				infestations with ticks,	•	148		
					alone or in association				
					with fleas and/or				
					chewing lice				
					cnewing lice				

Dre	oduct	•	Marketing	The	erapeutic area		IA/CVMP	Eu	ropean Commission
PIC		•	authorisation	•	Target species	•	Validation	•	Opinion received
•	Invented name		holder	•	Summary of	•	Opinion	•	Date of decision
•	INN			•	indication	•	Active time	•	Notification
						•	Clock stop	•	Official Journal
•	MS-H Vaccine	•	Pharmsure	•	Chickens	•	15/12/2009	•	08/04/2011
•	Mycoplasma		Ltd	•	Vaccine to reduce air	•	07/04/2011	•	14/06/2011
	<i>synoviae</i> strain				sac lesions and	•	206		
	MS-H				reduce the number of	•	271		
					eggs with abnormal shell formation				
					caused by				
					Mycoplasma synoviae				
•	Recuvyra	•	Nexcyon	•	Dogs	•	16/12/2009	•	05/05/2011
•	Fentanyl		Pharmaceutic	•	Control of post-	•	04/05/2011		00/00/2011
	5		als Ltd		operative pain	•	210		
					associated with major	•	294		
					orthopaedic and soft				
					tissue surgery			<u> </u>	
•	Emdocam	•	Emdoka bvba	•	Cattle, pigs, horses	•	18/05/2010	•	09/06/2011
•	Meloxicam			•	For treatment in	•	09/06/2011		
					respiratory infections,	•	175		
					diarrhoea and mastitis in cattle. For	•	211		
					treatment in non-				
					infectious locomotor				
					disorders and in				
					puerperal septicaemia				
					and toxaemia in pigs.				
					In horses for				
					treatment in musculo-				
					skeletal disorders as				
					well for the relief of				
					pain in equine colic.				
•	Proteq West	•	MERIAL	•	Horses	•	18/05/2010	•	09/06/2011
	Nile			•	Vaccine for the active	•	09/06/2011		
•	West Nile				immunisation of	•	196 190		
	recombinant canarypox				horses against West Nile disease	•	170		
	virus (vCP2017								
	virus)								
•	Zulvac 1 Bovis	•	Pfizer Limited	•	Cattle	•	12/08/2010	•	06/07/2011
•	Inactivated			•	Active immunisation	•	09/06/2011		
	Bluetongue				of cattle for the	•	180		
	virus, serotype				prevention of	•	120		
	1, strain BTV-1				viraemia caused by				
					Bluetongue Virus, serotype 1				
					serviype I				
L		I		I				I	

Pro	duct	•	Marketing	The	erapeutic area	ΕN	IA/CVMP	Eu	ropean Commission
•	Invented name INN		authorisation holder	•	Target species Summary of indication	•	Validation Opinion Active time Clock stop	•	Opinion received Date of decision Notification Official Journal
•	Zulvac 1 Ovis Inactivated Bluetongue Virus, serotype 1, strain BTV-1	•	Pfizer Limited	•	Sheep Active immunisation of sheep for the prevention of viraemia caused by Bluetongue Virus, serotype 1	• • •	15/07/2010 09/06/2011 179 148	•	06/07/2011
•	Nobivac Myxo- RHD Live myxoma vectored RHD virus strain 009	•	Intervet International BV,	•	Rabbits Active immunisation of rabbits to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease	•	16/02/2010 14/07/2011 210 302	•	15/07/2011
•	Recocam Meloxicam	•	CF Pharma	•	Cattle, pigs, horses For treatment in respiratory infections, diarrhoea and mastitis in cattle. For treatment in non- infectious locomotor disorders and in puerperal septicaemia and toxaemia in pigs. In horses for treatment in musculo- skeletal disorders as well for the relief of pain in equine colic.	•	16/03/2010 14/07/2011 210 274	•	14/07/2011

CVMP opinions in 2011 on establishment of MRLs for new substances

Positive opinions

 Substance INN Methylpredni – solone 	Target species Bovine	EMA/CVMP Validation Opinion Active time Clock stop n/a 12/01/2011 90	European Commission Opinion received Date of regulation Official Journal 27/01/2011
(after provisional MRLs)		• 0	
Octenidine dihydrochloride	All mammalian food producing species	 11/08/2009 08/02/2011 210 246 	• 21/02/2011
Monepantel (after provisional MRLs)	Caprine	 n/a 09/03/2011 90 0 	• 25/03/2011
Azamethiphos	• Fin fish	 21/02/2011 07/04/2011 45 0 	• 08/04/2011
 Pegylated bovine granulocyte colony stimulating factor 	• Bovine	 16/03/2010 05/05/2011 210 205 	• 18/05/2011
Lasalocid	Bovine	 10/08/2010 05/05/2011 210 58 	• 18/05/2011
Ivermectin	All mammalian food producing species	 n/a 09/06/2011 176 0 	• 20/06/2011
Phenoxymethyl- penicillin	Poultry eggs	 12/10/2010 14/07/2011 210 65 	• 22/07/2011

Arbitrations and Community referrals in 2011

Type of referral	Date of clock startCVMP opinion	Product nameINN
Referral under Art. 34 of Directive	• 11/11/2009	Fortekor vet and associated names
2001/82/EC		Benazepril hydrochloride
Referral under Art. 34	• 14/04/2010	Synulox Lactating Cow and associated names
of Directive 2001/82/EC	• 07/06/2011	Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Combimox Lactating Cow
33(4) of Directive 2001/82/EC	• 07/04/2011	• Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Nisamox Lactating Cow
33(4) of Directive 2001/82/EC	• 07/04/2011	• Amoxicillin, clavulanic acid, prednisolone
Referral under Art.	• 14/07/2010	Combisyn Lactating Cow
33(4) of Directive 2001/82/EC	• 07/04/2011	• Amoxicillin, clavulanic acid, prednisolone
Referral under Art. 34	• 14/07/2010	Doxycycline 50% WSP and associated names
of Directive 2001/82/EC	• 04/05/2011	Doxycycline hyclate
Referral under Art. 34	• 14/07/2010	Doxyfar 50% WSP and associated names
of Directive	• 04/05/2011	Doxycycline hyclate
2001/82/EC		
Referral under Art. 34	• 09/11/2010	Baytril 10% oral solution and associated
of Directive 2001/82/EC		names
		Enrofloxacin
Referral under Art.	• 09/02/2011	Clavudale 50 mg tablet for cats and dogs
33(4) of Directive 2001/82/EC	• 08/06/2011	Amoxicillin and clavulanic acid
Referral under Art. 35	• 09/03/2011	Veterinary medicinal products containing
of Directive		active substances belonging to the class of
2001/82/EC		flukicides for which no MRL has been
		established in milk
Referral under Art. 35	• 06/04/2011	All veterinary medicinal products containing
of Directive 2001/82/EC		systemically administered (parenteral and oral) 3rd and 4th generation cephalosporins
		and intended for use in food producing
		species
		Cefquinome and ceftiofur
Referral under Art.	• 04/05/2011	Prontax 10 mg/ml solution for injection for
33(4) of Directive 2001/82/EC		sheep, cattle and pigs
		Doramectin

Type of referral	Date of clock startCVMP opinion	Product name INN
Referral under Art. 33(4) of Directive 2001/82/EC	• 04/05/2011	Prontax 5 mg/ml pour-on solution for cattleDoramectin
Referral under Art. 35 of Directive 2001/82/EC	• 04/05/2011	 All pre-mixes for medicated feedingstuffs containing 40, 100 or 200 g tilmicosin per kg pre-mix Tilmicosin
Referral under Art. 78 of Directive 2001/82/EC	04/05/201114/07/2011	 HIPRABOVIS PNEUMOS Emulsion for injection for cattle and associated names Inactivated <i>Mannheimia haemolytica</i> and <i>Histophilus somni</i>

Guidelines and working documents in 2011

CVMP Efficacy

Reference number	Document title	Status
EMA/CVMP/016/00-Rev.2	Guideline on the conduct of bioequivalence studies for veterinary medicinal products	Adopted April 2011
EMA/CVMP/760764/2010	Concept paper on the revision of the CVMP Guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances	Adopted for consultation, April 2011 (End of consultation 31 July 2011)
EMA/CVMP/EWP/459868/2008	Guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish	Adopted May 2011

CVMP Environmental Risk Assessment

Reference number	Document title	Status
EMA/CVMP/ERA/147844/2011	Reflection paper on the testing strategy and risk assessment for plants	Adopted for consultation, March 2011 (End of consultation 30 June 2011)
EMA/CVMP/ERA/430327/2009	Guideline on determining the fate of veterinary medicinal products in manure	Adopted March 2011
EMA/CVMP/ERAWP/409328/2010	Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products	Adopted for consultation, May 2011 (End of consultation 31 August 2011)

Reference number	Document title	Status
EMA/CVMP/ERA/172074/2008- Rev.3	Questions and answers document on implementation of ERA Guideline in support of VICH guidelines (GL 6 and GL 38)	Adopted July 2011

CVMP Immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/206555/2010	Guideline on requirements for the production and control of immunological veterinary medicinal products	Adopted for consultation, March 2011 (End of consultation 30 September 2011)
EMA/CVMP/IWP/314550/2010	Guideline on the design of studies to evaluate the safety and efficacy of fish vaccines	Adopted for consultation, March 2011 (End of consultation 30 September 2011)

CVMP Pharmacovigilance

_	1	T
Reference number	Document title	Status
EMA/CVMP/PhVWP/471721/2006	Recommendation on the basic surveillance of EudraVigilance Veterinary (EVVet) data	Adopted February 2011
EMA/CVMP/PhVWP/44873/2011	Public bulletin - Veterinary pharmacovigilance for 2010	Adopted February 2011
EMA/CVMP/10418/2009-Rev.3	CVMP combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products	Adopted June 2011
EMA/CVMP/PhVWP/377827/2011	List of species and breeds for electronic reporting of suspected adverse reactions in veterinary pharmacovigilance	Adopted June 2011
EMA/CVMP/PhVWP/288284/2007- Rev.4	Quidance notes on the use of VeDDRA terminology for reporting suspected adverse reactions in animals and humans	Adopted June 2011
SOP/V/4019	Standard operating procedure - Annual review of standard lists to be used in EudraVigilance Veterinary	Adopted June 2011

CVMP Scientific Advisory Group on Antimicrobials

Reference number	Document title	Status
EMA/CVMP/SAGAM/736964/2009	Reflection paper on meticillin- resistant <i>Staphylococcus</i> <i>pseudintermedius</i> (MRSP)	Adopted January 2011

General

Reference number	Document title	Status
EMA/347137/2010	Summary of procedures for consultation by CVMP of Scientific Advisory Groups (SAGs) and ad-hoc expert groups functioning as SAGs in relation to applications for authorisation for veterinary medicinal products	Adopted February 2011
EMA/CVMP/287420/2010	CVMP Strategy on antimicrobials 2011-2015	Adopted July 2011
EMA/CVMP/414812/2011	Question and answer document on the CVMP guideline on the SPC for antimicrobial products	Adopted July 2011